Loading...
•
Sep 30
Sotera Health Q3 2025 Earnings Report
Sotera Health reported strong Q3 2025 results with revenue growth of 9.1%, net income of $48.4 million, and a double-digit increase in Adjusted EBITDA.
Key Takeaways
Sotera Health delivered a strong performance in Q3 2025, reporting solid revenue growth across its business segments and expanding profitability. Sterigenics and Nordion achieved double-digit growth, while Nelson Labs improved segment income despite a revenue decline. Adjusted EPS rose significantly year-over-year.
Net revenue increased 9.1% YoY to $311.3 million
Net income grew to $48.4 million, or $0.17 per diluted share
Adjusted EBITDA rose 12.2% to $164.2 million, with a margin of 52.7%
Sterigenics and Nordion segments reported double-digit income growth
Sotera Health
Sotera Health
Sotera Health Revenue by Segment
Revenue by Segment
Sterigenics Revenue
CapyFin.comNordion Revenue
CapyFin.comNelson Labs Revenue
CapyFin.com Forward Guidance
Sotera Health raised its full-year Adjusted EBITDA growth forecast to 6.75%–7.75% and reaffirmed its revenue growth outlook, supported by continued operational momentum and cost discipline.
Positive Outlook
- Adjusted EPS guidance raised to $0.81–$0.86
- Adjusted EBITDA growth forecast increased to 6.75%–7.75%
- Revenue outlook reaffirmed at 4.5%–6.0% constant currency growth
- Improved interest expense forecast to $154M–$158M
- Lowered capital expenditure range to $125M–$135M
Challenges Ahead
- Inflationary pressures could affect margins
- EO-related litigation and settlement costs remain a risk
- Dependence on uninterrupted EO and Co-60 supply continues
- Product mix pressure affected Nordion’s income margin
- Nelson Labs still experiencing YoY revenue decline
Revenue & Expenses
Visualization of income flow from segment revenue to net income